Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18807253 | 1-CYCLOPROPYL-6-FLUORO-7-(4-((5-(4-METHOXYBENZYLIDENEAMINO)-2-THIOXO-1,3,4- THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3- CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY AND ANTICANCER COMPOUND | August 2024 | November 2024 | Allow | 3 | 1 | 0 | No | No |
| 18804443 | PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | August 2024 | October 2024 | Allow | 2 | 1 | 0 | No | No |
| 18617768 | NEUTROPHIL EXOCYTOSIS INHIBITORS | March 2024 | August 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18439666 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | February 2024 | April 2024 | Allow | 2 | 0 | 0 | No | No |
| 18518285 | 4-((2-(2-(2-(4-HYDROXYPHENYL)-4,5-DIPHENYL-1H-IMIDAZOL-1- YL)ACETYL)HYDRAZONO)METHYL)BENZOIC ACID AS AN ANTICANCER COMPOUND | November 2023 | January 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18512463 | 4-((2-(2-(2-(4-METHOXYPHENYL)-4,5-DIPHENYL-1H-IMIDAZOL-1-YL)ACETYL)HYDRAZONO)METHYL)BENZOIC ACID AS AN ANTI-CANCER COMPOUND | November 2023 | February 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18388901 | 5-(1H-INDOL-3-YL)-1,3-SUBSTITUTEDPYRIMIDO[4,5-D]PYRIMIDINE-2,4,7(1H,3H,8H)-TRIONE AS ANTICANCER AGENTS | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18388756 | 7-(4-((5-(BENZYLIDENEAMINO)-2-THIOXO-1,3,4-THIADIAZOL-3(2H)- YL)METHYL)PIPERAZIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4- DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY AND ANTICANCER COMPOUND | November 2023 | February 2024 | Allow | 3 | 0 | 0 | No | No |
| 18386777 | CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF | November 2023 | July 2024 | Allow | 8 | 1 | 1 | No | No |
| 18468583 | PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID STATE FORMS THEREOF | September 2023 | November 2023 | Allow | 2 | 0 | 0 | No | No |
| 18239233 | 5-SPIRO 9,10-DIHYDROANTHRACENE DERIVATIVE OF IMIDAZOLIDINE-2,4-DIONE AS AN ANTICANCER AGENT | August 2023 | January 2024 | Allow | 5 | 1 | 0 | No | No |
| 18448144 | Lurbinectedin Composition and Methods Making the Same | August 2023 | June 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18448097 | STABLE LURBINECTEDIN COMPOSITION | August 2023 | July 2024 | Abandon | 11 | 1 | 0 | No | No |
| 18214831 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | June 2023 | October 2023 | Allow | 4 | 1 | 0 | No | No |
| 18334924 | KRAS G12D MODULATING COMPOUNDS | June 2023 | March 2024 | Allow | 9 | 1 | 0 | No | No |
| 18320591 | TREATMENTS WITH NIROGACESTAT | May 2023 | June 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18252339 | DUAL TNFR1 ANTAGONISTS AND TNFR2 AGONISTS FOR USE IN RENAL DISEASES | May 2023 | May 2024 | Allow | 12 | 1 | 0 | Yes | No |
| 18131309 | PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | April 2023 | July 2023 | Allow | 4 | 1 | 0 | No | No |
| 18187489 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | March 2023 | May 2024 | Allow | 14 | 0 | 0 | No | No |
| 18123748 | PYRIDO[3,4-B]INDOL-1-ONE COMPOUNDS AS ANTICANCER AGENTS | March 2023 | August 2023 | Allow | 5 | 1 | 0 | No | No |
| 18116204 | DIHYDROMYRICETIN NANOCRYSTALS AND PREPARATION METHOD AND APPLICATIONN THEREOF | March 2023 | August 2023 | Allow | 6 | 1 | 0 | No | No |
| 18147066 | PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID STATE FORMS THEREOF | December 2022 | August 2023 | Allow | 7 | 1 | 0 | No | No |
| 18002717 | SUBSTITUTED 1-(3,3-DIFLUOROPIPERIDIN-4-YL)-IMIDAZO[4,5-C] QUINOLIN-2-ONE COMPOUNDS WITH BLOOD-BRAIN BARRIER PENETRABLE CAPABILITY | December 2022 | December 2023 | Allow | 11 | 1 | 0 | No | No |
| 18066056 | INHIBITORS OF MET KINASE | December 2022 | April 2023 | Allow | 4 | 0 | 0 | No | No |
| 18065579 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | December 2022 | October 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18078389 | OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | December 2022 | July 2024 | Allow | 19 | 1 | 0 | No | No |
| 18063626 | TRICYCLIC PYRIDONES AND PYRIMIDONES | December 2022 | August 2023 | Allow | 8 | 1 | 0 | No | No |
| 18051826 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | November 2022 | April 2023 | Allow | 15 | 1 | 0 | No | No |
| 17973182 | SUBSTITUTED DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND AND A COMPOSITION CONTAINING THE COMPOUND AND USE THEREOF | October 2022 | November 2024 | Allow | 25 | 1 | 0 | No | No |
| 17957392 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | September 2022 | March 2023 | Allow | 5 | 1 | 0 | No | No |
| 17941367 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | September 2022 | August 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17891462 | RABEXIMOD COMPOUNDS | August 2022 | March 2023 | Allow | 7 | 1 | 0 | No | No |
| 17886863 | SOLID FORMS OF 7-[[(1S)-1-[4-[(1S)-2-CYCLOPROPYL-1-(4-PROP-2-ENOYLPIPERAZIN-1-YL)ETHYL]PHENYL]ETHYL]AMINO]-1-ETHYL-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE | August 2022 | May 2023 | Allow | 9 | 0 | 0 | No | No |
| 17817548 | COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXY-N,N-DIMETHYLTRYPTAMINE | August 2022 | December 2022 | Allow | 4 | 1 | 0 | No | No |
| 17816614 | 2-OXINDOLE COMPOUNDS | August 2022 | July 2024 | Allow | 23 | 1 | 0 | No | No |
| 17858875 | CITRATE SALT, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME | July 2022 | April 2023 | Allow | 9 | 1 | 1 | No | No |
| 17850505 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AS IMMUNOMODULATORS | June 2022 | November 2024 | Allow | 28 | 1 | 0 | No | No |
| 17846819 | AMPK ACTIVATORS | June 2022 | September 2024 | Abandon | 27 | 0 | 1 | No | No |
| 17841613 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | June 2022 | April 2024 | Allow | 22 | 1 | 0 | Yes | No |
| 17837129 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | June 2022 | August 2024 | Allow | 26 | 1 | 0 | Yes | No |
| 17835331 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | June 2022 | October 2023 | Allow | 16 | 1 | 0 | No | No |
| 17824205 | HEMI-CITRATE SALTS OF GABA-A POSITIVE ALLOSTERIC MODULATOR AND CRYSTALLINE FORM THEREOF | May 2022 | February 2023 | Allow | 9 | 1 | 1 | No | No |
| 17744339 | Composition for Treatment of Muscular Disorders | May 2022 | February 2024 | Allow | 21 | 0 | 0 | No | No |
| 17743313 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | May 2022 | February 2024 | Allow | 21 | 1 | 0 | No | No |
| 17741050 | PYRIDINE DERIVATIVES WITH C-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | May 2022 | December 2023 | Allow | 19 | 2 | 0 | No | No |
| 17662512 | ZWITTERIONIC COMPOUNDS AS GAS CHROMATOGRAPHIC COLUMN STATIONARY PHASES | May 2022 | April 2024 | Allow | 23 | 1 | 0 | No | No |
| 17737131 | RAS INHIBITORS | May 2022 | January 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17660873 | COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXY-N,N-DIMETHYLTRYPTAMINE | April 2022 | June 2022 | Allow | 2 | 1 | 0 | No | No |
| 17660541 | GLS1 INHIBITORS FOR TREATING DISEASE | April 2022 | December 2023 | Allow | 19 | 1 | 0 | No | No |
| 17723979 | USE OF GABOXADOL IN THE TREATMENT OF SUBSTANCE USE DISORDERS | April 2022 | June 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17721636 | THIENOPYRROLE COMPOUNDS | April 2022 | February 2023 | Allow | 10 | 0 | 0 | Yes | No |
| 17719432 | 3H,4H-THIENO[2,3-D]PYRIMIDIN-4-ONE DERIVATIVES AS TRPA1 INHIBITORS | April 2022 | August 2024 | Allow | 28 | 1 | 0 | No | No |
| 17706690 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | March 2022 | April 2024 | Allow | 25 | 1 | 0 | No | No |
| 17702703 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | March 2022 | October 2022 | Allow | 7 | 1 | 0 | No | No |
| 17701478 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | March 2022 | June 2023 | Allow | 15 | 1 | 0 | Yes | No |
| 17760818 | CRYSTAL FORM OF HEPATITIS B SURFACE ANTIGEN INHIBITOR AND APPLICATION THEREOF | March 2022 | July 2023 | Allow | 16 | 0 | 0 | No | No |
| 17691764 | METHODS, COMPOSITIONS, AND KITS FOR TREATING AND/OR PREVENTING A SIDE EFFECT ASSOCIATED WITH RADIATION AND/OR CHEMOTHERAPY EXPOSURE | March 2022 | July 2024 | Allow | 28 | 1 | 0 | No | No |
| 17679746 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | February 2022 | November 2023 | Allow | 21 | 1 | 0 | No | No |
| 17753162 | HALOGEN-SUBSTITUTED PHENYLATE COMPOUND AND APPLICATIONS THEREOF | February 2022 | December 2023 | Allow | 22 | 2 | 0 | Yes | No |
| 17676684 | ANTI-CANCER, ANTI-INFLAMMATORY AND IMMUNOMODULATORY ACTIVITY OF R-CARVEDILOL AND METHODS OF USE | February 2022 | July 2024 | Abandon | 29 | 2 | 0 | No | No |
| 17668621 | INHIBITING FATTY ACID SYNTHASE (FASN) | February 2022 | October 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17669135 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | February 2022 | May 2023 | Allow | 16 | 1 | 0 | No | No |
| 17666350 | TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | February 2022 | June 2024 | Allow | 28 | 2 | 0 | No | No |
| 17633336 | A CRYSTALLINE FORM AND B CRYSTALLINE FORM OF PYRAZINE-2(1H)-KETONE COMPOUND AND PREPARATION METHOD THEREOF | February 2022 | January 2023 | Allow | 11 | 1 | 0 | Yes | No |
| 17592348 | GPR119 AGONISTS | February 2022 | April 2022 | Allow | 3 | 0 | 0 | No | No |
| 17590401 | TARGETING EPIDERMAL GROWTH FACTOR TO TREAT VASCULAR CALCIFICATION | February 2022 | November 2022 | Allow | 9 | 1 | 1 | Yes | No |
| 17558130 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | December 2021 | August 2024 | Allow | 32 | 3 | 0 | No | No |
| 17554831 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | December 2021 | June 2023 | Allow | 18 | 1 | 0 | No | No |
| 17644969 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | December 2021 | December 2023 | Allow | 24 | 1 | 0 | No | No |
| 17644473 | TABLET FORMULATION OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YLMETHYL)IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE | December 2021 | October 2024 | Allow | 34 | 2 | 0 | No | No |
| 17544863 | MODULATORS OF P97 AAA ATPASE ACTIVITY | December 2021 | May 2023 | Allow | 17 | 1 | 0 | Yes | No |
| 17531397 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | November 2021 | June 2022 | Allow | 60 | 1 | 1 | No | No |
| 17610835 | Crystal Form of Quinazolinone Compound and Preparation Method Therefor | November 2021 | February 2023 | Abandon | 15 | 1 | 0 | No | No |
| 17524759 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | November 2021 | April 2023 | Allow | 17 | 1 | 0 | Yes | No |
| 17521711 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | November 2021 | March 2022 | Allow | 4 | 1 | 0 | Yes | No |
| 17500593 | PHENALENE-1-ONE-CONTAINING PHOTOSENSITIZER COMPOSITION, PHENALENE-1-ONE COMPOUND AND THE USE THEREOF | October 2021 | October 2023 | Allow | 24 | 1 | 0 | No | No |
| 17495935 | ACETAMIDO-PHENYLTETRAZOLE DERIVATIVES AND METHODS OF USING THE SAME | October 2021 | April 2023 | Allow | 18 | 1 | 0 | No | No |
| 17449696 | BICYCLIC DIONE COMPOUNDS AS INHIBITORS OF KRAS | October 2021 | May 2023 | Allow | 19 | 1 | 0 | No | No |
| 17480323 | CDK Inhibitors And Their Use As Pharmaceuticals | September 2021 | December 2022 | Allow | 15 | 0 | 0 | No | No |
| 17479341 | CRYSTALLINE FORM OF N-BUTYLDEOXYGALACTONOJIRIMYCIN | September 2021 | March 2023 | Allow | 18 | 1 | 0 | No | No |
| 17440630 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | September 2021 | April 2024 | Allow | 31 | 0 | 0 | No | No |
| 17464260 | QUINOLIN-2(1H)-ONE INHIBITORS OF LATE SV40 FACTOR | September 2021 | April 2022 | Allow | 8 | 1 | 0 | No | No |
| 17397509 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | August 2021 | September 2024 | Abandon | 37 | 2 | 1 | No | No |
| 17382664 | SMALL ORGANIC MOLECULES FOR USE IN THE TREATMENT OF NEUROINFLAMMATORY DISORDERS | July 2021 | July 2023 | Allow | 23 | 1 | 0 | No | No |
| 17423153 | PREPARATION METHOD FOR MORPHOLINQUINAZOLINE COMPOUND AND INTERMEDIATES THEREOF | July 2021 | August 2022 | Allow | 13 | 1 | 0 | No | No |
| 17370884 | AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF | July 2021 | May 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17358385 | AMPK ACTIVATORS | June 2021 | October 2021 | Allow | 4 | 1 | 0 | Yes | No |
| 17355063 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | June 2021 | August 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17304154 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | June 2021 | May 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17339896 | Niraparib Compositions | June 2021 | January 2023 | Allow | 20 | 1 | 0 | No | No |
| 17338420 | CRYSTALLINE FORMS OF IRAK DEGRADERS | June 2021 | February 2023 | Allow | 20 | 1 | 0 | No | No |
| 17336759 | ULTRAPURE TETRAHYDROCANNABINOL-11-OIC ACIDS | June 2021 | September 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17330162 | MODULATING EXPRESSION LEVEL OF A GENE ENCODING A HEAT SHOCK PROTEIN BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | May 2021 | March 2022 | Allow | 9 | 1 | 1 | Yes | No |
| 17326633 | MTORC MODULATORS AND USES THEREOF | May 2021 | March 2023 | Allow | 21 | 1 | 0 | No | No |
| 17309270 | SPIRO COMPOUND AND MEDICAL USES THEREOF | May 2021 | August 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17315567 | SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE | May 2021 | October 2022 | Allow | 17 | 0 | 0 | No | No |
| 17308879 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | May 2021 | April 2023 | Allow | 23 | 1 | 0 | Yes | No |
| 17242913 | C7, C12, AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | April 2021 | January 2024 | Allow | 33 | 1 | 1 | No | No |
| 17238986 | CRYSTAL FORMS OF AN ALK2 INHIBITOR | April 2021 | April 2024 | Allow | 36 | 1 | 0 | No | No |
| 17287612 | SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS | April 2021 | August 2024 | Allow | 40 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MAURO, JOHN MATTHEW.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MAURO, JOHN MATTHEW works in Art Unit 1625 and has examined 686 patent applications in our dataset. With an allowance rate of 87.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 18 months.
Examiner MAURO, JOHN MATTHEW's allowance rate of 87.9% places them in the 68% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by MAURO, JOHN MATTHEW receive 1.32 office actions before reaching final disposition. This places the examiner in the 19% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by MAURO, JOHN MATTHEW is 18 months. This places the examiner in the 96% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +20.3% benefit to allowance rate for applications examined by MAURO, JOHN MATTHEW. This interview benefit is in the 64% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 35.8% of applications are subsequently allowed. This success rate is in the 81% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 72.6% of cases where such amendments are filed. This entry rate is in the 93% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 39.1% are granted (fully or in part). This grant rate is in the 28% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 51% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.